The week at a glance
Between March 22 and March 29, DataLookout processed 46,689 clinical trials and detected 47 protocol changes, 942 newly posted trials, and 83 new sponsor entrants.
Where new sponsors are entering
A "new entrant" means a sponsor filed their first-ever trial in a disease area. It's one of the strongest early signals in competitive intelligence. It usually means a strategic expansion, an acquired asset moving into the clinic, or a fast-follower play after a competitor's positive readout.
This week's top disease areas by new sponsor activity:
| # | Disease Area | New Entrants | |
|---|---|---|---|
| 1 | Stroke | 7 | |
| 2 | Diabetes | 6 | |
| 3 | Hypertension | 5 | |
| 3 | Obesity | 5 | |
| 5 | Anxiety | 4 | |
| 5 | Breast Cancer | 4 | |
| 5 | Coronary Artery Disease | 4 | |
| 8 | Chronic Kidney Disease | 3 | |
| 8 | Heart Disease | 3 | |
| 8 | Heart Failure | 3 |
Why stroke is at the top
Stroke leading with 7 new sponsors is worth paying attention to. The cerebrovascular space has picked up momentum recently, with renewed interest in neuroprotection and next-generation clot retrieval devices.
Several of this week's entrants are academic medical centers launching investigator-initiated trials. That pattern often precedes industry interest. Academic groups identify a target, generate early clinical data, and industry sponsors follow with larger, registration-quality studies.
Diabetes and obesity attracting new entrants isn't a surprise. The GLP-1 boom is still pulling new companies into metabolic disease. But the question for the next 6 months is whether the market is getting crowded enough that late entrants will struggle to differentiate.
Most active sponsors by protocol changes
On the other side of the intelligence picture: which sponsors are modifying their existing trials? Status changes, endpoint amendments, enrollment updates, and site additions all show up here.
| # | Sponsor | Changes | |
|---|---|---|---|
| 1 | Karuna Therapeutics | 4 | |
| 2 | Merck Sharp & Dohme LLC | 3 | |
| 3 | Sanofi | 2 | |
| 3 | National Cancer Institute (NCI) | 2 | |
| 3 | NHLBI | 2 |
Karuna Therapeutics, acquired by Bristol-Myers Squibb in March 2024, had four protocol changes this week across their schizophrenia and neuropsychiatry pipeline. When an acquired company's trials start changing in clusters like this, it usually signals portfolio integration and prioritization decisions by the acquiring company.
Get these signals delivered to you
Add a disease to your watchlist. When a new sponsor enters, you'll know the same week it happens.
Start Monitoring Free